Ra Pharmctl Inc (NASDAQ:RARX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Separately, Jefferies Group LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of Ra Pharmctl in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $27.00.

Shares of Ra Pharmctl (RARX) opened at 15.02 on Tuesday. The stock has a 50 day moving average price of $15.27 and a 200-day moving average price of $20.26. The firm’s market capitalization is $339.59 million. Ra Pharmctl has a 52-week low of $12.05 and a 52-week high of $27.84.

Ra Pharmctl (NASDAQ:RARX) last posted its earnings results on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by $0.06. Equities analysts forecast that Ra Pharmctl will post ($2.33) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/24/ra-pharmctl-inc-rarx-stock-rating-lowered-by-zacks-investment-research.html.

In other news, major shareholder Bioventures Ltd Novartis sold 5,353 shares of the business’s stock in a transaction on Friday, May 26th. The shares were sold at an average price of $25.14, for a total transaction of $134,574.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have sold 139,795 shares of company stock valued at $3,176,269. Insiders own 14.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. American International Group Inc. purchased a new position in shares of Ra Pharmctl during the first quarter valued at $102,000. TIAA CREF Investment Management LLC increased its position in shares of Ra Pharmctl by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Ra Pharmctl by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares in the last quarter. Alliancebernstein L.P. purchased a new position in shares of Ra Pharmctl during the second quarter valued at $195,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Ra Pharmctl by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after buying an additional 2,543 shares in the last quarter. 61.77% of the stock is owned by institutional investors.

Ra Pharmctl Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Stock Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related stocks with our FREE daily email newsletter.